ArticleBMJ (Clinical research ed.)2003
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
Article in BMJ (Clinical research ed.), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 144 citations in OpenAlex.
- Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab Emirates.Therapeutic advances in neurological disorders · 2025Article
- Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review.Health economics review · 2024Review
- Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain.Journal of comparative effectiveness research · 2023Article
- How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review.Neurology and therapy · 2021Review
- Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model.Medical decision making : an international journal of the Society for Medical Decision Making · 2020Article
- Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis.Drugs & aging · 2020Article
- Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.Journal of neurology, neurosurgery, and psychiatry · 2019Observational
- Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China.Clinical drug investigation · 2019Article
- Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.CNS drugs · 2018Article
- Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.PharmacoEconomics - open · 2018Review
- Replicating Health Economic Models: Firm Foundations or a House of Cards?PharmacoEconomics · 2017Article
- Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling.PharmacoEconomics · 2017Article
- Multiple sclerosis: relapses, resource use, and costs.The European journal of health economics : HEPAC : health economics in prevention and care · 2016Article
- Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS.Global journal of health science · 2014Article
- Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.PharmacoEconomics · 2014Review
- Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2014Article
- UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.BMJ open · 2014Article
- Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2013Article
- Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.PharmacoEconomics · 2013Review
- Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom.The European journal of health economics : HEPAC : health economics in prevention and care · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom.
designModelling cost effectiveness.
settingUK NHS.
participantsPatients with relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis.
main outcome measuresCost per quality adjusted life year gained.
resultsThe base case cost per quality adjusted life year gained by using any of the four treatments ranged from pound 42,000 (66,469 dollars; 61,630 euro) to pound 98,000 based on efficacy information in the public domain. Uncertainty analysis suggests that the probability of any of these treatments having a cost effectiveness better than pound 20,000 at 20 years is below 20%. The key determinants of cost effectiveness were the time horizon, the progression of patients after stopping treatment, differential discount rates, and the price of the treatments.
conclusionsCost effectiveness varied markedly between the interventions. Uncertainty around point estimates was substantial. This uncertainty could be reduced by conducting research on the true magnitude of the effect of these drugs, the progression of patients after stopping treatment, the costs of care, and the quality of life of the patients. Price was the key modifiable determinant of the cost effectiveness of these treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.